Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Has signed a written informed consent prior to the first study evaluation;~2. Male or female is at least 20 and \< 80 years of age;~3. Diabetes mellitus (type 1 or 2) with an HbA1c \< 12.0% measured during screening or within three months prior to randomization;~4. An ankle brachial index on the target limb at least 0.8 measured during screening or within three months prior to randomization;~5. The target ulcer must have the following characteristics:~   * Grade 1 or 2 per Wagner Ulcer Classification System;~  * No higher than the ankle;~  * No active infected;~  * A cross-sectional area of between 1 and 25 cm2 post-debridement;~  * Present for at least 4 weeks before randomization;~6. If female and of childbearing potential has a negative pregnancy test and is not breastfeeding at screening visit;~7. Able and willing to attend the scheduled visits and comply with study procedures.~Exclusion Criteria:~1. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;~2. Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;~3. Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb \< 4 weeks prior to randomization;~4. Poor nutritional status defined as an albumin \< 2.5 g/dL;~5. Aspartate Aminotransferase(AST, GOT) and/or Alanine Aminotransferase(ALT, GPT) \>3 x the normal upper limit;~6. Serum Creatinine \>2 x the normal upper limit;~7. Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 4 weeks before randomization;~8. Use of any investigational drug or therapy within the 4 weeks prior to randomization;~9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance;~10. Judged by the investigator not to be suitable for the study for any other reason.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ON101 Cream (Type: EXPERIMENTAL): ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
- Aquacel® Hydrofiber® dressing (Type: OTHER): Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).